



01-08-04

Certificate of Express Mailing

Express Mail Label No.: EV 312852701 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 and is addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

By: _____

Barbara Bryant

Date: _____

January 7, 2004

Patent

Attorney's Docket No. P-154-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MORAN et al.

Application No.: 10/627,555

Filed: July 25, 2003

For: CRYSTALLINE β_2 ADRENERGIC
RECEPTOR AGONIST

)
)
) Group Art Unit: Not yet assigned

)
) Examiner: Not yet assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 CFR §1.56, Applicants hereby submit the following information in conformance with CFR §§1.97 and 1.98. Enclosed herewith is form PTO-1449 which lists documents for consideration by the Examiner. Copies of the cited documents are also enclosed herewith.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

Consideration of the listed documents is respectfully requested. Additionally, the Examiner is respectfully requested to return an initialed copy of the enclosed form PTO-1449 to Applicants.

The document listed as C1 on the enclosed form PTO-1449 was cited in the International Search Report mailed on December 19, 2003, for the corresponding PCT Application No. PCT/US03/23214. A copy of the International Search Report is enclosed for the convenience of the Examiner.

This Information Disclosure Statement is being filed before the mailing date of a first official action on the merits for this application and therefore, no fee or certification is required under 37 CFR §1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees under 37 CFR §1.97(c) for submission of this paper to Deposit Account No. 50-0344.

Should there be any questions concerning the cited documents, the Examiner is encouraged to telephone the undersigned agent for Applicants at (650) 808-3764 (direct).

Respectfully submitted,

THERAVANCE, INC.

Date: January 7, 2004

By: Roberta P. Saxon
Roberta P. Saxon, Ph.D.
Registration No. 43,087

THERAVANCE, INC.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000
Fax: (650) 808-6078

OTIP
JAN 07 2004
PATENT & TRADEMARK OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/627,555
Filing Date	July 25, 2003
First Named Inventor	Martin S. LINSELL
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	P-154-US1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	B1	WO 02/070490 A1	09-12-2002	Glaxo Group Limited		
	B2	WO 03/024439 A1	03-27-2003	Glaxo Group Limited		
	B3	WO 03/072539 A1	09-04-2003	Glaxo Group Limited		
	B4	WO 03/091204 A1	11-06-2003	Glaxo Group Limited		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	MALAMAS et al., "Potent, Selective Aminothiazolidinediones Agonists of the Human β_3 Adrenergic Receptor", Med Chem Res 10:3, pp 164-177 (2000)	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.